Nouscom raises $135M in Series D for lead cancer vaccine
Clinical-stage cancer biotech Nouscom has raised $135 million in an oversubscribed Series D funding round to take its lead vaccine through to a Phase 2 study. “We're super excited because there is the potential of ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
